ASCIA transplantation and primary immunodeficiency (TAPID) project

Abstract

Introduction: The Australasian Society of Clinical Immunology and Allergy (ASCIA) transplantation and primary immunodeficiency (TAPID) project is an important and ongoing collaboration between clinical immunologists, transplant physicians and international experts, facilitated by ASCIA. The main objective of the TAPID project is to facilitate collaborations and regular (monthly) discussions between clinical immunologists and transplant physicians in major centres in Australia and New Zealand that have primary immunodeficiency (PID) patients who are candidates for haematopoietic stem cell transplants (HSCT). Methods: Since the first TAPID face to face meeting was held in February 2014, the TAPID project membership has increased from 12 to over 90 members. Teleconferences are now held each month and face to face meetings have been held in Melbourne in 2017 (20-21 May) and 2018 (5-6 May). Case discussion forms (deidentified) are completed for each case and these are circulated to the group prior to each meeting. More than 90 cases have been discussed since 2014. Conclusion: HSCT is an important and potentially life-saving treatment option for some PIDs, particularly T cell disorders. These are complex disorders and patients benefit greatly from a team-based approach to management. The ASCIA TAPID project enables these complex PID and transplantation cases to be discussed in a confidential multi-national expert forum, to help improve patient outcomes.L6251340412018-11-28 <br />